- Home
- MAIA vs CGTX Comparison
MAIA vs CGTX Comparison
Compare MAIA & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAIA
- CGTX
- Stock Information
- Founded
- MAIA 2018
- CGTX 2007
- Country
- MAIA United States
- CGTX United States
- Employees
- MAIA N/A
- CGTX N/A
- Industry
- MAIA Biotechnology: Pharmaceutical Preparations
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- MAIA Health Care
- CGTX Health Care
- Exchange
- MAIA Nasdaq
- CGTX Nasdaq
- Market Cap
- MAIA 56.3M
- CGTX 53.4M
- IPO Year
- MAIA 2022
- CGTX 2021
- Fundamental
- Price
- MAIA $1.67
- CGTX $2.17
- Analyst Decision
- MAIA
- CGTX Strong Buy
- Analyst Count
- MAIA 0
- CGTX 3
- Target Price
- MAIA N/A
- CGTX $2.83
- AVG Volume (30 Days)
- MAIA 450.2K
- CGTX 8.0M
- Earning Date
- MAIA 11-11-2025
- CGTX 11-12-2025
- Dividend Yield
- MAIA N/A
- CGTX N/A
- EPS Growth
- MAIA N/A
- CGTX N/A
- EPS
- MAIA N/A
- CGTX N/A
- Revenue
- MAIA N/A
- CGTX N/A
- Revenue This Year
- MAIA N/A
- CGTX N/A
- Revenue Next Year
- MAIA N/A
- CGTX N/A
- P/E Ratio
- MAIA N/A
- CGTX N/A
- Revenue Growth
- MAIA N/A
- CGTX N/A
- 52 Week Low
- MAIA $1.40
- CGTX $0.22
- 52 Week High
- MAIA $3.62
- CGTX $3.83
- Technical
- Relative Strength Index (RSI)
- MAIA 56.55
- CGTX 52.79
- Support Level
- MAIA $1.54
- CGTX $2.33
- Resistance Level
- MAIA $1.78
- CGTX $2.60
- Average True Range (ATR)
- MAIA 0.09
- CGTX 0.34
- MACD
- MAIA 0.02
- CGTX -0.09
- Stochastic Oscillator
- MAIA 65.62
- CGTX 15.31
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.